These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20696087)

  • 1. Risk factors for fluoroquinolone resistance in Enterococcus urinary tract infections in hospitalized patients.
    Rattanaumpawan P; Tolomeo P; Bilker WB; Fishman NO; Lautenbach E
    Epidemiol Infect; 2011 Jun; 139(6):955-61. PubMed ID: 20696087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections.
    Rattanaumpawan P; Tolomeo P; Bilker WB; Fishman NO; Lautenbach E
    J Hosp Infect; 2010 Dec; 76(4):324-7. PubMed ID: 20643497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors associated with fluoroquinolone-resistant enterococcal urinary tract infections in a tertiary care university hospital in north India.
    Banerjee T; Anupurba S
    Indian J Med Res; 2016 Oct; 144(4):604-610. PubMed ID: 28256471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Community-acquired enterococcal urinary tract infections in hospitalized children.
    Marcus N; Ashkenazi S; Samra Z; Cohen A; Livni G
    Pediatr Nephrol; 2012 Jan; 27(1):109-14. PubMed ID: 21822790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vancomycin-resistant enterococcal urinary tract infections.
    Heintz BH; Halilovic J; Christensen CL
    Pharmacotherapy; 2010 Nov; 30(11):1136-49. PubMed ID: 20973687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli.
    Rattanaumpawan P; Nachamkin I; Bilker WB; Roy JA; Metlay JP; Zaoutis TE; Lautenbach E;
    Ann Clin Microbiol Antimicrob; 2017 Apr; 16(1):25. PubMed ID: 28390438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trimethoprim and enterococci in urinary tract infections: new perspectives on an old issue.
    Wisell KT; Kahlmeter G; Giske CG
    J Antimicrob Chemother; 2008 Jul; 62(1):35-40. PubMed ID: 18408238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for ambulatory urinary tract infections caused by high-MIC fluoroquinolone-susceptible Escherichia coli in women: results from a large case-control study.
    Rattanaumpawan P; Nachamkin I; Bilker WB; Roy JA; Metlay JP; Zaoutis TE; Lautenbach E;
    J Antimicrob Chemother; 2015 May; 70(5):1547-51. PubMed ID: 25630645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimethoprim/sulfamethoxazole resistance in urinary tract infections.
    Guneysel O; Onur O; Erdede M; Denizbasi A
    J Emerg Med; 2009 May; 36(4):338-41. PubMed ID: 18325714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America).
    Mathai D; Jones RN; Pfaller MA;
    Diagn Microbiol Infect Dis; 2001 Jul; 40(3):129-36. PubMed ID: 11502382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of enterococcal urinary tract infections in immunocompromised - neoplastic patients.
    Giannakopoulos X; Sakkas H; Ragos V; Tsiambas E; Bozidis P; M Evangelou A; Papadopoulou C; Petrogiannopoulos L; Sofikitis N
    J BUON; 2019; 24(5):1768-1775. PubMed ID: 31786836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High rates of quinolone resistance among urinary tract infections in the ED.
    Khawcharoenporn T; Vasoo S; Ward E; Singh K
    Am J Emerg Med; 2012 Jan; 30(1):68-74. PubMed ID: 21075586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study.
    Lam S; Singer C; Tucci V; Morthland VH; Pfaller MA; Isenberg HD
    Am J Infect Control; 1995 Jun; 23(3):170-80. PubMed ID: 7677262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the treatment of vancomycin-resistant enterococcal urinary tract infections in a large academic medical center.
    Heintz BH; Cho S; Fujioka A; Li J; Halilovic J
    Ann Pharmacother; 2013 Feb; 47(2):159-69. PubMed ID: 23341161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of fluoroquinolone-resistant UTI among US emergency department patients diagnosed with urinary tract infection, 2018-2020.
    Faine BA; Rech MA; Vakkalanka P; Gross A; Brown C; Harding SJ; Slocum G; Zimmerman D; Zepeski A; Rewitzer S; Howington GT; Campbell M; Dawson J; Treu CN; Nelson L; Jones M; Flack T; Porter B; Sarangarm P; Mattson AE; Bailey A; Kelly G; Talan DA
    Acad Emerg Med; 2022 Sep; 29(9):1096-1105. PubMed ID: 35652493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection.
    van der Starre WE; van Nieuwkoop C; Paltansing S; van't Wout JW; Groeneveld GH; Becker MJ; Koster T; Wattel-Louis GH; Delfos NM; Ablij HC; Leyten EM; Blom JW; van Dissel JT
    J Antimicrob Chemother; 2011 Mar; 66(3):650-6. PubMed ID: 21123286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefazolin versus fluoroquinolones for the treatment of community-acquired urinary tract infections in hospitalized patients.
    Uppala A; King EA; Patel D
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1533-1538. PubMed ID: 31114972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey of the susceptibility of urinary isolates to antibacterial agents in 2003.
    Ishikawa K; Hayakawa S; Miyakawa S; Kusaka M; Shiroki R; Hoshinaga K
    J Infect Chemother; 2005 Feb; 11(1):44-7. PubMed ID: 15729488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation and risk factor profiling of Pseudomonas aeruginosa urinary tract infections: pinpointing those likely to be caused by multidrug-resistant strains.
    Tumbarello M; Raffaelli F; Peghin M; Losito AR; Chirico L; Giuliano G; Spanu T; Sartor A; Fiori B; Bassetti M
    Int J Antimicrob Agents; 2020 Apr; 55(4):105900. PubMed ID: 31931150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of Enterococcus as a significant pathogen.
    Moellering RC
    Clin Infect Dis; 1992 Jun; 14(6):1173-6. PubMed ID: 1623072
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.